SI1636215T1 - Furazanobenzimidazoli - Google Patents
FurazanobenzimidazoliInfo
- Publication number
- SI1636215T1 SI1636215T1 SI200430636T SI200430636T SI1636215T1 SI 1636215 T1 SI1636215 T1 SI 1636215T1 SI 200430636 T SI200430636 T SI 200430636T SI 200430636 T SI200430636 T SI 200430636T SI 1636215 T1 SI1636215 T1 SI 1636215T1
- Authority
- SI
- Slovenia
- Prior art keywords
- compounds
- formula
- carbonyl group
- neoplastic
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Reproductive Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preventing Corrosion Or Incrustation Of Metals (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03405365 | 2003-05-23 | ||
| PCT/IB2004/001723 WO2004103994A1 (en) | 2003-05-23 | 2004-05-19 | Furazanobenzimidazoles |
| EP04733874A EP1636215B1 (en) | 2003-05-23 | 2004-05-19 | Furazanobenzimidazoles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI1636215T1 true SI1636215T1 (sl) | 2008-06-30 |
Family
ID=33462273
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200430636T SI1636215T1 (sl) | 2003-05-23 | 2004-05-19 | Furazanobenzimidazoli |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US7385061B2 (sl) |
| EP (1) | EP1636215B1 (sl) |
| JP (2) | JP4829791B2 (sl) |
| CN (1) | CN100434428C (sl) |
| AT (1) | ATE384718T1 (sl) |
| CA (1) | CA2526026C (sl) |
| CY (1) | CY1107422T1 (sl) |
| DE (1) | DE602004011515T2 (sl) |
| DK (1) | DK1636215T3 (sl) |
| ES (1) | ES2300775T3 (sl) |
| PL (1) | PL1636215T3 (sl) |
| PT (1) | PT1636215E (sl) |
| SI (1) | SI1636215T1 (sl) |
| WO (1) | WO2004103994A1 (sl) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1472245A2 (en) * | 2002-02-06 | 2004-11-03 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds useful as inhibitors of gsk-3 |
| ES2346323T3 (es) * | 2004-02-11 | 2010-10-14 | Basilea Pharmaceutica Ag | Bencimidazoles sustituidos y su uso para inducir apoptosis. |
| US7625890B2 (en) | 2005-11-10 | 2009-12-01 | Smithkline Beecham Corp. | Substituted imidazo[4,5-c]pyridine compounds as Akt inhibitors |
| BR112012001817B8 (pt) * | 2009-07-27 | 2021-05-25 | Basilea Pharmaceutica Ag | furazanobenzimidazóis, seu uso, processo de produção e composição farmacêutica |
| EP2666015B1 (en) * | 2011-01-21 | 2016-12-28 | Basilea Pharmaceutica AG | Use of stathmin as a biomarker of drug response to furazanobenzimidazoles |
| PL2666016T3 (pl) * | 2011-01-21 | 2017-07-31 | Basilea Pharmaceutica Ag | Zastosowanie BUBR1 jako biomarkera odpowiedzi lekowej |
| US9995754B2 (en) * | 2011-01-21 | 2018-06-12 | Basilea Pharmaceutica Ag | Use of glu-tubulin as a biomarker of drug response to furazanobenzimidazoles |
| ES2621413T3 (es) * | 2011-02-24 | 2017-07-04 | Basilea Pharmaceutica Ag | Uso de tubulina acetilada como un biomarcador de la respuesta de fármacos a furazanobencimidazoles |
| ES2627972T3 (es) * | 2011-03-29 | 2017-08-01 | Basilea Pharmaceutica Ag | Uso de fosfo-Akt como un biomarcador de la respuesta a fármacos |
| CN108139405B (zh) * | 2015-10-22 | 2022-06-10 | 巴斯利尔药物国际股份公司 | Eb1作为药物应答的生物标记物的用途 |
| CN116947836A (zh) | 2017-04-26 | 2023-10-27 | 巴斯利尔药物国际股份公司 | 制备呋咱并苯并咪唑及其晶型的方法 |
| WO2018202850A1 (en) | 2017-05-05 | 2018-11-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Microtubule-targeting drugs as immune checkpoint inhibitors and methods of screening novel immune checkpoint inhibitors for the treatment of cancers and infectious diseases |
| EP3624790A1 (en) | 2017-05-16 | 2020-03-25 | Basilea Pharmaceutica International AG | Novel dosage principle for drugs useful for treating neoplastic diseases |
| US11419856B2 (en) | 2017-11-20 | 2022-08-23 | Basilea Pharmaceutica International AG | Pharmaceutical combinations for use in the treatment of neoplastic diseases |
| US20220031670A1 (en) | 2018-09-20 | 2022-02-03 | Basilea Pharmaceutica International AG | Pharmaceutical combinations for use in the treatment of neoplastic diseases |
| EP4027998A1 (en) | 2019-09-09 | 2022-07-20 | Basilea Pharmaceutica International AG | Pharmaceutical combinations comprising a furazanobenzimidazoles and a cd40 agonist for use in the treatment of neoplastic diseases |
| CN111454254B (zh) * | 2020-04-26 | 2023-06-02 | 云白药征武科技(上海)有限公司 | 一种具有含氟取代基的苯并咪唑衍生物的制备及其应用 |
| CN111423429A (zh) * | 2020-05-19 | 2020-07-17 | 江西科技师范大学 | 苯并咪唑联呋咱类系列化合物及其合成方法 |
| WO2022053549A1 (en) | 2020-09-10 | 2022-03-17 | Basilea Pharmaceutica International AG | Use of c-myc as a biomarker of drug response |
| GB202101734D0 (en) * | 2021-02-08 | 2021-03-24 | Cerevance Inc | Novel Compounds |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4269846A (en) * | 1979-10-29 | 1981-05-26 | Usv Pharmaceutical Corporation | Heterocyclic compounds useful as anti-allergy agents |
| DE3100771A1 (de) | 1981-01-13 | 1982-08-26 | USV Pharmaceutical Corp., Tuckahoe, N.Y. | Heterocyclische verbindungen, verfahren zu ihrer herstellung und sie enthaltende arzneimittel |
| DE4307105A1 (de) * | 1993-03-06 | 1994-09-08 | Cassella Ag | Hydroxymethylfurazancarbonsäurederivate |
| US6110935A (en) * | 1997-02-13 | 2000-08-29 | The Regents Of The University Of California | Benzofurazan compounds for enhancing glutamatergic synaptic responses |
| EP1472245A2 (en) * | 2002-02-06 | 2004-11-03 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds useful as inhibitors of gsk-3 |
| CL2003002353A1 (es) | 2002-11-15 | 2005-02-04 | Vertex Pharma | Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic |
-
2004
- 2004-05-19 PL PL04733874T patent/PL1636215T3/pl unknown
- 2004-05-19 DE DE602004011515T patent/DE602004011515T2/de not_active Expired - Lifetime
- 2004-05-19 CA CA2526026A patent/CA2526026C/en not_active Expired - Lifetime
- 2004-05-19 AT AT04733874T patent/ATE384718T1/de active
- 2004-05-19 WO PCT/IB2004/001723 patent/WO2004103994A1/en active IP Right Grant
- 2004-05-19 SI SI200430636T patent/SI1636215T1/sl unknown
- 2004-05-19 EP EP04733874A patent/EP1636215B1/en not_active Expired - Lifetime
- 2004-05-19 JP JP2006530690A patent/JP4829791B2/ja not_active Expired - Lifetime
- 2004-05-19 US US10/557,539 patent/US7385061B2/en not_active Ceased
- 2004-05-19 CN CNB2004800177608A patent/CN100434428C/zh not_active Expired - Fee Related
- 2004-05-19 US US12/796,135 patent/USRE42890E1/en not_active Expired - Lifetime
- 2004-05-19 DK DK04733874T patent/DK1636215T3/da active
- 2004-05-19 PT PT04733874T patent/PT1636215E/pt unknown
- 2004-05-19 ES ES04733874T patent/ES2300775T3/es not_active Expired - Lifetime
-
2008
- 2008-04-23 CY CY20081100454T patent/CY1107422T1/el unknown
-
2011
- 2011-06-21 JP JP2011137578A patent/JP5670266B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP1636215A1 (en) | 2006-03-22 |
| USRE42890E1 (en) | 2011-11-01 |
| DE602004011515T2 (de) | 2009-01-29 |
| JP4829791B2 (ja) | 2011-12-07 |
| WO2004103994A1 (en) | 2004-12-02 |
| CN100434428C (zh) | 2008-11-19 |
| CA2526026C (en) | 2012-03-20 |
| CA2526026A1 (en) | 2004-12-02 |
| US7385061B2 (en) | 2008-06-10 |
| EP1636215B1 (en) | 2008-01-23 |
| PT1636215E (pt) | 2008-04-29 |
| PL1636215T3 (pl) | 2008-09-30 |
| ATE384718T1 (de) | 2008-02-15 |
| JP5670266B2 (ja) | 2015-02-18 |
| DE602004011515D1 (de) | 2008-03-13 |
| CY1107422T1 (el) | 2012-12-19 |
| JP2006528238A (ja) | 2006-12-14 |
| DK1636215T3 (da) | 2008-06-02 |
| US20070043061A1 (en) | 2007-02-22 |
| CN1812986A (zh) | 2006-08-02 |
| JP2011207909A (ja) | 2011-10-20 |
| ES2300775T3 (es) | 2008-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1107422T1 (el) | Φουραζανοβενζιμιδαζoλες | |
| NO20050741L (no) | Ny fremgangsmate for syntesen og ny krystallinsk form av agomelatin og farmasoytiske sammensetninger inneholdende den | |
| HUP0303756A2 (hu) | 1-Aril- vagy 1-alkilszulfonil-heterociklobenzazolok és eljárás ezek elõállítására és ezeket tartalmazó gyógyszerkészítmények | |
| DE602005022284D1 (de) | Substituierte benzimidazole und deren verwendung zur induktion von apoptose | |
| SE0300119D0 (sv) | Novel compounds | |
| TW200626553A (en) | Novel compounds | |
| IL164007A (en) | Compounds and pharmaceutical compositions inhibiting histone deacetylase, their use and process for their manufacture | |
| TW200724136A (en) | Pharmaceutical compositions comprising PPAR modulator | |
| NZ545692A (en) | PPAR-activating compound and pharmaceutical composition containing same | |
| MXPA02012425A (es) | Compuestos nuevos. | |
| NO20075169L (no) | Nye imidazo (1,5-A)pyndindenvater, fremgangsmate for fremstilling og farmasoytiske sammensetninger som inneholder samme. | |
| HK1082250A1 (en) | Thiophene carboxamides as inhibitors of the enzymeikk-2 | |
| HUP0300080A2 (hu) | Új malonsavszármazékok, eljárás előállításukra, ezek alkalmazása Xa faktor inhibitorként és ezeket tartalmazó gyógyszerkészítmények | |
| TW200616636A (en) | Novel compounds | |
| WO2005037798A3 (en) | Amide or thiomide derivatives and their use in the treatment of pain | |
| SE0302139D0 (sv) | Novel compounds | |
| ATE381554T1 (de) | Aroylfurane und aroylthiophene, die sich für die behandlung von krebs eignen | |
| SE0302116D0 (sv) | Novel compounds | |
| ATE482933T1 (de) | Sulfopyrrolderivate | |
| MY146802A (en) | Novel drugs for treating respiratory diseases | |
| SE0300092D0 (sv) | Novel compounds | |
| MXPA05010020A (es) | Derivados de oxamida. | |
| PL1789044T3 (pl) | Fenyloaminopirydyny i fenyloaminopirazyny | |
| SE0401763D0 (sv) | Compounds | |
| MXPA05014068A (es) | Dicetopiperazinas sustituidas y su uso como antagonistas de oxitocina. |